EGFR and lung cancer: Several large scaled studies showed epidermal growth factor receptor (EGFR) - tyrosine kinase inhibitors (TKIs) were associated with a good response rate approximating 70% as well as a progression-free survival (PFS) rate of 9-13 months in patients with lung cancer harboring EGFR activating mutations [1–5].